Sinovac Biotech (SVA) – Company Press Releases
-
Sinovac Amends Shareholder Rights Plan
-
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
-
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
-
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress
-
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress
-
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress
-
Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting
-
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
-
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
-
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
-
Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device
-
Sernova Corporation Announces the Appointment of Cynthia Pussinen as CEO
-
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
-
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
-
Sinovac Announces Change of Legal Representative of Sinovac Beijing
-
SINOVAC Reports Unaudited First Half of 2023 Financial Results
-
Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer
-
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
-
Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessions
-
Sernova to Participate in Upcoming Truist Securities Cell Therapy Symposium
-
Sernova Announces Executive Alignment and Appoints New Board Chair
-
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines
-
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
-
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
-
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC., Recommend Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
-
UPDATE -- Institutional Shareholder Services Inc. Recommends Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
-
Institutional Shareholder Services Inc. Recommends Senova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
-
Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates
-
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes As
-
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
-
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
-
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
-
Sinovac Amends Shareholder Rights Plan
-
Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy
-
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
-
SINOVAC Reports Unaudited First Half of 2022 Financial Results
-
Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
-
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
-
Sernova to Participate in the Stifel Healthcare Conference
-
SINOVAC Varicella Vaccine Prequalified by WHO
-
Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes
-
SINOVAC to Showcase Products at CPHI Frankfurt
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MINISO, Co-Dx, Ampio, and Sinovac and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MINISO, Co-Dx, Ampio, and Sinovac and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MINISO, Co-Dx, Ampio, and Sinovac and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MINISO, Co-Dx, Ampio, and Sinovac and Encourages Investors to Contact the Firm
-
Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ampio, Sinovac, Lottery.com, and NIO and Encourages Investors to Contact the Firm
-
Sernova Announces Full Exercise of Share Purchase Warrants Expiring September 22, 2022
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Co-Dx, Ampio, Sinovac, and Lottery.com and Encourages Investors to Contact the Firm
Back to SVA Stock Lookup
